Article
Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.
Cancer biomarkers : section A of Disease markers - 1 Jan 2023
Lin Chih-Lang, Chien Rong-Nan, Chen Li-Wei, Chu Yu-De, Yeh Chau-Ting
Abstract excerpt
BACKGROUND: Sorafenib and lenvatinib are tyrosine kinase inhibitors widely used in the targeted therapy to treat advanced hepatocellular carcinoma (aHCC). The GALNT14-rs9679162 genotype is a predictor of therapeutic outcome in multiple gastrointestinal cancers. OBJECTIVE: To investigate the predictive role of the GALNT14-rs9679162 genotype in aHCC treated with sorafenib or lenvatinib. METHODS: Totally 350...
Topics
Join the communities discussing this publication.
